Private Capital Management LLC Has $56.87 Million Position in Harrow, Inc. (NASDAQ:HROW)

Private Capital Management LLC decreased its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 21.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,694,983 shares of the company's stock after selling 468,698 shares during the period. Harrow accounts for about 6.0% of Private Capital Management LLC's investment portfolio, making the stock its 2nd largest holding. Private Capital Management LLC owned 4.76% of Harrow worth $56,867,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HROW. Barclays PLC increased its holdings in shares of Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company's stock valued at $2,365,000 after buying an additional 39,506 shares in the last quarter. Brookstone Capital Management bought a new position in shares of Harrow in the fourth quarter valued at $275,000. SG Americas Securities LLC increased its holdings in shares of Harrow by 158.5% in the fourth quarter. SG Americas Securities LLC now owns 30,689 shares of the company's stock valued at $1,030,000 after buying an additional 18,815 shares in the last quarter. Sonora Investment Management Group LLC bought a new position in shares of Harrow in the fourth quarter valued at $518,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Harrow by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock valued at $253,000 after buying an additional 727 shares in the last quarter. Institutional investors own 72.76% of the company's stock.

Harrow Stock Up 10.9%

NASDAQ:HROW traded up $2.79 during trading hours on Friday, hitting $28.41. 633,665 shares of the stock traded hands, compared to its average volume of 498,095. The firm has a 50 day moving average price of $25.02 and a 200 day moving average price of $31.91. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a fifty-two week low of $15.97 and a fifty-two week high of $59.23. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -30.22 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The firm had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. Equities research analysts anticipate that Harrow, Inc. will post -0.53 earnings per share for the current year.

Wall Street Analyst Weigh In

HROW has been the topic of several research reports. B. Riley dropped their price target on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. HC Wainwright boosted their target price on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, May 12th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.